Stereotactic Body Radiotherapy for Centrally Located Primary Non–Small-Cell Lung Cancer

A Meta-Analysis

Tosol Yu, In Soo Shin, Won Sup Yoon, Chai Hong Rim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The feasibility of stereotactic body radiotherapy (SBRT) for centrally located tumors is controversial. SBRT with 100 Gy or higher biologically equivalent dose using an α/β of 10 Gy for centrally located primary NSCLC offered excellent local control (3years; 77.6% [95% confidential interval, 65.2-86.5]), comparable with that of other SBRT reports for peripheral lung tumors. The pooled rate of Grade ≥3 complications was 12.0%. This suggest that SBRT can be used in inoperable centrally located lung tumors with a curative intent.

Original languageEnglish
JournalClinical Lung Cancer
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Radiosurgery
Non-Small Cell Lung Carcinoma
Meta-Analysis
Neoplasms
Lung

Keywords

  • Dose fractionation
  • Network meta-analysis
  • Non–small-cell lung carcinoma
  • Radiosurgery
  • Survival rate

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Stereotactic Body Radiotherapy for Centrally Located Primary Non–Small-Cell Lung Cancer : A Meta-Analysis. / Yu, Tosol; Shin, In Soo; Yoon, Won Sup; Rim, Chai Hong.

In: Clinical Lung Cancer, 01.01.2019.

Research output: Contribution to journalArticle

@article{aa196ba31b5b482ab92034a890d95e67,
title = "Stereotactic Body Radiotherapy for Centrally Located Primary Non–Small-Cell Lung Cancer: A Meta-Analysis",
abstract = "The feasibility of stereotactic body radiotherapy (SBRT) for centrally located tumors is controversial. SBRT with 100 Gy or higher biologically equivalent dose using an α/β of 10 Gy for centrally located primary NSCLC offered excellent local control (3years; 77.6{\%} [95{\%} confidential interval, 65.2-86.5]), comparable with that of other SBRT reports for peripheral lung tumors. The pooled rate of Grade ≥3 complications was 12.0{\%}. This suggest that SBRT can be used in inoperable centrally located lung tumors with a curative intent.",
keywords = "Dose fractionation, Network meta-analysis, Non–small-cell lung carcinoma, Radiosurgery, Survival rate",
author = "Tosol Yu and Shin, {In Soo} and Yoon, {Won Sup} and Rim, {Chai Hong}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2019.02.023",
language = "English",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Stereotactic Body Radiotherapy for Centrally Located Primary Non–Small-Cell Lung Cancer

T2 - A Meta-Analysis

AU - Yu, Tosol

AU - Shin, In Soo

AU - Yoon, Won Sup

AU - Rim, Chai Hong

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The feasibility of stereotactic body radiotherapy (SBRT) for centrally located tumors is controversial. SBRT with 100 Gy or higher biologically equivalent dose using an α/β of 10 Gy for centrally located primary NSCLC offered excellent local control (3years; 77.6% [95% confidential interval, 65.2-86.5]), comparable with that of other SBRT reports for peripheral lung tumors. The pooled rate of Grade ≥3 complications was 12.0%. This suggest that SBRT can be used in inoperable centrally located lung tumors with a curative intent.

AB - The feasibility of stereotactic body radiotherapy (SBRT) for centrally located tumors is controversial. SBRT with 100 Gy or higher biologically equivalent dose using an α/β of 10 Gy for centrally located primary NSCLC offered excellent local control (3years; 77.6% [95% confidential interval, 65.2-86.5]), comparable with that of other SBRT reports for peripheral lung tumors. The pooled rate of Grade ≥3 complications was 12.0%. This suggest that SBRT can be used in inoperable centrally located lung tumors with a curative intent.

KW - Dose fractionation

KW - Network meta-analysis

KW - Non–small-cell lung carcinoma

KW - Radiosurgery

KW - Survival rate

UR - http://www.scopus.com/inward/record.url?scp=85064611157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064611157&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2019.02.023

DO - 10.1016/j.cllc.2019.02.023

M3 - Article

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -